BioWorld

Sep. 5, 2003

Epimmune Trimming Staff, Costs To Help Develop Pipeline Drugs

Epimmune Inc. reduced its staff by 23 percent and implemented other cost-cutting measures that the company said would give it enough operating funds to pull results from ongoing clinical trials in HIV and cancer. (BioWorld Today) Read More

Theratechnologies Enters Deal With J&J In Area Of Diabetes

Vaccine Spurs Immune System To Attack B. anthracis Plus Its Toxins, Beating Current Vaccines

Pozen Licenses MT 300 Rights To Xcel In Deal Worth At Least $10M

Cerus, Baxter Stop Phase III Of S-303 In Precautionary Move

Other News To Note

Today's news in brief

BioWorld

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...

Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent

BioWorld Science

Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...